CD40 and type 1 diabetes mellitus: One of the notable characteristics of the DC generated from monocytic progenitors in the presence of the mixture of antisense DNA targeting the primary transcripts of CD40, CD80, and CD86 used in the phase I type 1 diabetes safety trial is their ability to produce retinoic acid (RA) (16, 17).